CooperVision
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, CooperVision sits in the top decile of US sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count).
CooperVision: 64 sponsored US clinical trials, 2 recruiting.
CooperVision sponsors 64 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 61 completed. The most-studied condition in this pipeline is Myopia, with 13 trials.
Top-decile sponsor footprint
CooperVision ranks in the top decile of sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
61 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (98.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
64 total, page 1 of 2
MiSight 1 Day Safety Post-Approval Study
NCT05285527
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553
1 Week Crossover Study Between Two Soft Contact Lenses
NCT06611410
Performance Evaluation of Reusable Contact Lenses When Worn For One Month By Habitual Soft Contact Lens Wearers
NCT06098339
Performance Evaluation of Different Daily Disposable Silicone Hydrogel Contact Lenses
NCT05805059
Performance Evaluation of Daily Disposable Contact Lenses in Habitual Lens Wearers Who Use Digital Devices Frequently
NCT05805150
Performance Evaluation of Different Daily Disposable Multifocal Contact Lenses
NCT05763628
Evaluating Two Multifocal Daily Disposable Contact Lenses
NCT05579886
Evaluation of Monthly Replacement Lenses in Habitual Soft Contact Lens Wearers Who Report Frequent Digital Devise Use
NCT05166902
Evaluation of the Performance of Monthly Replacement Sphere Lens Designs in Habitual Soft Contact Lens Wearers
NCT05114564
Evaluating the Success of Habitual Multifocal Wearers When Refit With a New Lens Design
NCT04952701
Clinical Validation of the Apollo Daily Disposable Soft Contact Lenses
NCT05035017
Performance Evaluation of Two Daily Disposable Toric Lens Designs in Habitual Soft Contact Lens Wearers
NCT04831515
Evaluation of the Performance of Different Daily Disposable Lens Designs in Habitual Soft Contact Lens Wearers
NCT04668989
A Two-Week Crossover Dispensing Evaluation Of Orion Daily Wear Soft Contact Lens
NCT04585646
Comparing Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism
NCT04404725
Comparing the Performance of 1 Day Multifocal Contact Lenses
NCT04449263
Evaluation Of One Silicone Hydrogel Contact Lens and Two Hydrogel Lenses in Daily Wear
NCT04050618
Clinical Evaluation of Invigor Toric 1-Day Contact Lenses
NCT04016623
A Dispensing Comparison of a Test Daily 1 Day Lens Against a Control 1 Day Lens.
NCT03951610
Comparison of Two Daily Disposable Soft Contact Lenses
NCT03779503
Evaluation of Silicone Hydrogel Daily Wear Contact Lenses for Up to One (1) Month of Daily Wear
NCT03722784
Performance of Wearers of Stenfilcon A Contact Lenses After A Refit With Test Lenses
NCT03496701
A Dispensing Clinical Trial of Test Contact Lens Against Marketed Contact Lens
NCT03499067
Clinical Validation Study of Comfilcon A Multifocal Toric Contact Lenses
NCT03417557
Comparison of New Contact Lens With Current Marketed Lens
NCT03360110
A One-Week Crossover Dispensing Evaluation of New Daily Wear Soft Contact Lenses
NCT03306641
A 6-Hour Clinical Evaluation of New Daily-Wear Soft Contact Lenses
NCT03235089
Daily Disposable Dispensing Clinical Trial of Test Lens Against Stenfilcon A Lens
NCT03024970
Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses
NCT02956460
Performance of Fanfilcon A Toric Lenses After at Least One Month Wearing Enfilcon A Toric Lenses
NCT02921412
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
NCT02920957
One Month Dispensing Study Comparing the Clinical Performance of the Comfilcon A Sphere Lenses Compared to Comfilcon A Asphere Lenses.
NCT02759471
A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses
NCT02719353
A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses
NCT02719366
Dispensing Study for a New Study Lens
NCT02642991
Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear
NCT02555722
A Bilateral Dispensing Clinical Trial of an Sapphire Lens Against Senofilcon A Toric for Astigmatism Lens
NCT02555098
Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses
NCT02423109
One Week Assessment of The Phenacite Lens
NCT02553395
A Contralateral Dispensing Clinical Trial of Study Test Sapphire Lens Against Enfilcon A Silicone Hydrogel Lens
NCT02518490
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
NCT02542072
Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism
NCT02410824
Dispensing Study for the Phenacite Project
NCT02436005
Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear
NCT02362724
Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®
NCT02341859
A Bilateral Dispensing Clinical Trial of Sapphire Lens Against Senofilcon A Lens Over 2 Weeks
NCT02345811
Multicenter Dispensing Study of Biofinity Toric Made-To-Order Lenses in Extended Power Ranges
NCT02193178
Clinical Validation of Biofinity Toric MTO (Made To Order) Lenses
NCT02185105
Clinical Evaluation of Daily Disposable Contact Lenses
NCT02097030
Therapeutic Areas
What is open in the CooperVision pipeline
2 recruiting of 64 indexed (3% open); 61 completed (95%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Myopia (13 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CooperVision: open-pipeline peers nationwide
Peers matched on 64 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
CooperVision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 64 trials (± recruiting share)
- Cephalon · 64 trials · 0% recruiting
- NRG Oncology · 64 trials · 47% recruiting
- University of Houston · 64 trials · 20% recruiting
- Washington State University · 64 trials · 30% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Allina Health System · 3% recruiting · 32 trials
- Masimo Corporation · 3% recruiting · 96 trials
- MiMedx Group · 3% recruiting · 32 trials
- Sharp HealthCare · 3% recruiting · 32 trials
Related
What to do with this CooperVision page
64 registered trials is a research-attention snapshot, not an endorsement of CooperVision or any single study.
- 2 of CooperVision's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myopia is the condition CooperVision studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myopia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CooperVision pipeline card: 64 registered trials from official public datasets.Report a data error.